NO20085183L - Stabiliserte insulinlignende vekstfaktorpolypeptider - Google Patents

Stabiliserte insulinlignende vekstfaktorpolypeptider

Info

Publication number
NO20085183L
NO20085183L NO20085183A NO20085183A NO20085183L NO 20085183 L NO20085183 L NO 20085183L NO 20085183 A NO20085183 A NO 20085183A NO 20085183 A NO20085183 A NO 20085183A NO 20085183 L NO20085183 L NO 20085183L
Authority
NO
Norway
Prior art keywords
growth factor
factor polypeptides
stabilized insulin
igf
stabilized
Prior art date
Application number
NO20085183A
Other languages
English (en)
Inventor
Mara Fornaro
David Glass
Gopinath Rajuseetharaman
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38801859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20085183(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20085183L publication Critical patent/NO20085183L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)

Abstract

Oppfinnelsen er relatert til stabiliserte polypeptider som har en IGF-1 eller IGF-2 sekvens og en E-peptidsekvens, hvor den naturlige fysiologiske kløvingen av E-peptidet fra IGF er hindret.
NO20085183A 2006-06-09 2008-12-11 Stabiliserte insulinlignende vekstfaktorpolypeptider NO20085183L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81234906P 2006-06-09 2006-06-09
US86224406P 2006-10-20 2006-10-20
US89718707P 2007-01-24 2007-01-24
PCT/EP2007/055608 WO2007141309A2 (en) 2006-06-09 2007-06-06 Stabilized insulin-like growth factor polypeptides

Publications (1)

Publication Number Publication Date
NO20085183L true NO20085183L (no) 2009-03-09

Family

ID=38801859

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20085184A NO20085184L (no) 2006-06-09 2008-12-11 Stabiliserte insulinlignende vekstfaktorpolypeptider
NO20085183A NO20085183L (no) 2006-06-09 2008-12-11 Stabiliserte insulinlignende vekstfaktorpolypeptider

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20085184A NO20085184L (no) 2006-06-09 2008-12-11 Stabiliserte insulinlignende vekstfaktorpolypeptider

Country Status (33)

Country Link
US (4) US8343918B2 (no)
EP (2) EP2032155B1 (no)
JP (2) JP5290966B2 (no)
KR (1) KR101459789B1 (no)
AR (1) AR061242A1 (no)
AU (2) AU2007257936B2 (no)
BR (2) BRPI0712147A2 (no)
CA (2) CA2654944C (no)
CL (1) CL2007001614A1 (no)
CR (2) CR10432A (no)
CY (1) CY1116117T1 (no)
DK (2) DK2032155T3 (no)
EC (1) ECSP088949A (no)
ES (1) ES2529261T3 (no)
GT (1) GT200800273A (no)
HK (1) HK1126429A1 (no)
HR (1) HRP20150326T1 (no)
IL (1) IL195156A (no)
JO (1) JO2968B1 (no)
MA (1) MA30503B1 (no)
MX (2) MX2008015726A (no)
MY (1) MY147856A (no)
NO (2) NO20085184L (no)
NZ (2) NZ572548A (no)
PE (1) PE20080715A1 (no)
PL (1) PL2032155T3 (no)
PT (1) PT2032155E (no)
RU (1) RU2477287C2 (no)
SI (1) SI2032155T1 (no)
TN (1) TNSN08509A1 (no)
TW (1) TWI427084B (no)
UA (1) UA97953C2 (no)
WO (2) WO2007141309A2 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090318355A1 (en) * 2006-02-15 2009-12-24 Chen Thomas T Compositions and methods for promoting tissue repair and wound healing
UA97953C2 (uk) * 2006-06-09 2012-04-10 Новартіс Аг Стабілізовані поліпептиди інсуліноподібного фактора росту
EP2279210B1 (en) * 2008-05-07 2017-04-12 BioMarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
WO2010052344A2 (en) * 2008-11-10 2010-05-14 Novartis Ag Antibodies to modified human igf-1/e peptides
WO2010088502A2 (en) * 2009-01-30 2010-08-05 The Regents Of The University Of California Insulin-like growth factor signaling and integrin
LT2424895T (lt) 2009-04-27 2017-12-27 Novartis Ag Kompozicijos ir būdai, skirti raumenų augimo spartinimui
JP5571186B2 (ja) 2009-07-22 2014-08-13 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ ５９位にアミノ酸置換を有するインスリン様増殖因子−１（ｉｇｆ−１）の類似体
WO2011057249A2 (en) 2009-11-09 2011-05-12 The Brigham And Women's Hospital, Inc. Treatment of heart disease
JP2011160696A (ja) * 2010-02-08 2011-08-25 Novartis Ag 修飾ヒトｉｇｆ−１／ｅペプチドに対する抗体
JP6263773B2 (ja) 2011-02-23 2018-01-24 マサチューセッツ インスティテュート オブ テクノロジー 水溶性膜タンパク質およびその調製および使用方法
US20140357558A1 (en) * 2011-06-24 2014-12-04 Cold Spring Harbor Laboratory Compositions and methods for treatment of spinal muscular atrophy
HUE040276T2 (hu) 2011-07-01 2019-02-28 Novartis Ag Eljárás metabolikus rendellenességek kezelésére
WO2014012025A2 (en) 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Igf-1 proteins and therapeutic uses thereof
EP2935319B1 (en) * 2012-12-18 2019-04-24 Novartis AG Production of therapeutic proteins in genetically modified mammalian cells
ES2756330T3 (es) 2012-12-18 2020-04-27 Novartis Ag Polipéptidos de factor de crecimiento insulínico estabilizados
AU2014307589A1 (en) 2013-08-14 2016-02-11 Novartis Ag Methods of treating sporadic inclusion body myositis
EP3052123A1 (en) 2013-10-02 2016-08-10 Novartis Ag Insulin-like growth factor mimetics for use in therapy
UY35874A (es) * 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
KR102313381B1 (ko) * 2013-12-19 2021-10-14 퓨어테인 바이오사이언스, 엘엘씨. 동물을 치료하기 위한 방법
JP2017510622A (ja) 2014-01-27 2017-04-13 ノバルティス アーゲー 筋萎縮を予測するバイオマーカー、方法および使用
WO2015149085A2 (en) * 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Warer-soluble trans-membrane proteins and methods for the preparation and use thereof
US10373702B2 (en) 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
KR20170109570A (ko) * 2015-02-04 2017-09-29 퓨어테인 바이오사이언스, 엘엘씨. 자손에서의 성능 특성을 증가시키는 방법
KR101669140B1 (ko) 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
US11534466B2 (en) 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
RU2019129858A (ru) 2017-03-24 2021-03-23 Новартис Аг Методы профилактики и лечения сердечных заболеваний
JP6691503B2 (ja) * 2017-04-13 2020-04-28 任天堂株式会社 ゲームプログラム、ゲーム処理制御方法、およびゲーム装置
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
WO2023145961A1 (ja) * 2022-01-31 2023-08-03 国立大学法人信州大学 ＩＧＦ１Ｒを標的とするｐｒｅ－ｐｒｏ前駆体型キメラ抗原受容体発現細胞

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
ATE81779T1 (de) * 1985-08-22 1992-11-15 Gropep Pty Ltd Peptidanalogedes insulinaehnlichen wachstumsfaktors-1 bei saeugetieren.
JP2507106B2 (ja) 1987-12-24 1996-06-12 グロペップ プロプライエタリー リミテッド インスリン様成長因子１（ｉｇｆ―１）または因子２（ｉｇｆ―２）の類縁ペプチド
GB8819826D0 (en) * 1988-08-20 1988-09-21 Kabivitrum Ab Glycosylated igf-1
JPH07508025A (ja) * 1992-05-08 1995-09-07 トーマス・ジェファーソン・ユニバーシティ インスリン様増殖因子（ｉｇｆ−１）類似体
WO1995013290A1 (en) 1993-11-12 1995-05-18 North Shore University Hospital Research Corporation Method of treating muscular dystrophy
EP0756494A1 (en) 1994-05-24 1997-02-05 Amgen Boulder Inc. Modified insulin-like growth factors
GB9605124D0 (en) * 1996-03-11 1996-05-08 Royal Free Hosp School Med Method of treating muscular disorders
US7118752B2 (en) 1998-07-22 2006-10-10 University Of Connecticut Compositions and methods for inhibiting the proliferation and invasiveness of malignant cells comprising E-domain peptides of IGF-I
AU762351B2 (en) * 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
GB9926968D0 (en) * 1999-11-15 2000-01-12 Univ London Treatment of neurological disorders
GB0011278D0 (en) 2000-05-10 2000-06-28 Univ London Repair of nerve damage
AU2002303431C1 (en) * 2001-04-19 2008-03-06 The Regents Of The University Of California Methods and composition for the production of orthoganal tRNA-aminoacyltRNA synthetase pairs
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
EP2322201A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2005033134A2 (en) 2003-09-30 2005-04-14 Regeneron Pharmaceuticals, Inc. Secreted protein therapeutics and uses thereof
GB0426154D0 (en) 2004-11-29 2004-12-29 European Molecular Biology Lab Embl IGF-1 novel peptides
EP1674113A1 (en) * 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
HUE027645T2 (en) * 2005-01-07 2016-10-28 Regeneron Pharma IGF-1 fusion proteins and therapeutic applications
JP2008533114A (ja) 2005-03-18 2008-08-21 ユーシーエル ビジネス パブリック リミテッド カンパニー メカノ成長因子ペプチドおよびその使用
WO2006097764A1 (en) 2005-03-18 2006-09-21 Ucl Business Plc Mecano growth factor peptides and their use
US20090271875A1 (en) 2005-03-31 2009-10-29 Pioneer Corporation Upgrade Module, Application Program, Server, and Upgrade Module Distribution System
UA97953C2 (uk) 2006-06-09 2012-04-10 Новартіс Аг Стабілізовані поліпептиди інсуліноподібного фактора росту

Also Published As

Publication number Publication date
JP5290966B2 (ja) 2013-09-18
MY147856A (en) 2013-01-31
BRPI0712052A2 (pt) 2012-01-10
JP2009539805A (ja) 2009-11-19
RU2008151511A (ru) 2010-07-20
CL2007001614A1 (es) 2008-08-08
EP2032154A2 (en) 2009-03-11
PL2032155T3 (pl) 2015-05-29
NO20085184L (no) 2009-03-03
GT200800273A (es) 2009-09-16
HRP20150326T1 (hr) 2015-04-24
KR20090027197A (ko) 2009-03-16
SI2032155T1 (sl) 2015-04-30
US8343918B2 (en) 2013-01-01
US20100234290A1 (en) 2010-09-16
TW200835698A (en) 2008-09-01
DK200900016A (da) 2009-01-06
UA97953C2 (uk) 2012-04-10
TWI427084B (zh) 2014-02-21
WO2007146689A9 (en) 2010-12-16
US20140235538A1 (en) 2014-08-21
PT2032155E (pt) 2015-04-07
AU2007257936A1 (en) 2007-12-21
CA2653781A1 (en) 2007-12-13
MX2008015657A (es) 2009-02-04
EP2032155B1 (en) 2014-12-24
AU2007257936B2 (en) 2011-05-26
CA2654944C (en) 2017-01-03
CA2654944A1 (en) 2007-12-21
WO2007141309A3 (en) 2008-05-29
RU2477287C2 (ru) 2013-03-10
IL195156A0 (en) 2011-08-01
MX2008015726A (es) 2008-12-19
US20130059779A1 (en) 2013-03-07
DK2032155T3 (en) 2015-03-02
EP2032155A2 (en) 2009-03-11
AU2007255419A1 (en) 2007-12-13
US20170066808A9 (en) 2017-03-09
PE20080715A1 (es) 2008-07-25
WO2007146689A2 (en) 2007-12-21
US20100173839A1 (en) 2010-07-08
NZ572708A (en) 2011-11-25
WO2007141309A2 (en) 2007-12-13
TNSN08509A1 (en) 2010-04-14
JP2009539383A (ja) 2009-11-19
MA30503B1 (fr) 2009-06-01
CY1116117T1 (el) 2017-02-08
ES2529261T3 (es) 2015-02-18
KR101459789B1 (ko) 2014-11-07
US8722621B2 (en) 2014-05-13
HK1126429A1 (en) 2009-09-04
ECSP088949A (es) 2009-01-30
JO2968B1 (en) 2016-03-15
IL195156A (en) 2014-07-31
CR10432A (es) 2009-01-15
NZ572548A (en) 2011-06-30
CR20160115A (es) 2016-06-14
BRPI0712147A2 (pt) 2012-02-22
AR061242A1 (es) 2008-08-13
WO2007146689A3 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
NO20085183L (no) Stabiliserte insulinlignende vekstfaktorpolypeptider
NO20070983L (no) Stabil injiserbar blanding av alfa-tokoferylsuksinat, analoger og salter derav
NO2017025I1 (no) Rekombinant FSH (rFSH) innbefattende alfa2,3-sialylering og alfa2,6-sialylering hvor 80% eller mer av den totale sialylering er alfa2,3-sialylering og hvor fra 5% til 20% av den totale sialylering er alfa2,6- sialylering, spesielt follitropin delta.
WO2011020120A3 (en) Multi-transgenic pigs for diabetes treatment
DE602005020498D1 (de) Verfahren zur herstellung einer l-aminosäure unter verwendung eines bakteriums der familie enterobacteriaceae mit abgeschwächter expression des yafa-gens
WO2009007714A3 (en) Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour
WO2008002571A3 (en) Human protein tyrosine phosphatase inhibitors and methods of use
AR053259A1 (es) Trigo con nuevo almidon y metodo para producirlo
WO2007106690A3 (en) Degenerate nucleobase analogs
NO20080745L (no) Nye peptider for anvendelse i behandling av fedme
UA103623C2 (ru) Регулятор роста растений
GEP20146056B (en) Acylated glucagon analogues
NO20061026L (no) Nye insulinderivater
WO2008002570A3 (en) Human protein tyrosine phosphatase inhibitors and methods of use
PH12014501336A1 (en) Glucagon analogues
EP3461507A8 (en) Cell-scaffold constructs
WO2008002569A3 (en) Human protein tyrosine phosphatase inhibitors and methods of use
WO2009035540A3 (en) Analogues of exendin-4 and exendin-3
WO2007087384A3 (en) Methods for modulating mannose content of recombinant proteins
MX2009011287A (es) Defensina de planta modificada.
HK1139705A1 (en) Growth medium for c. histolyticum without ingredients of mamalian sources
ATE395826T1 (de) Verwendung von 3-(2,4,6-trimethylphenyl)-4- neopentylcarbonyloxy-5,5-tetramethylen- dihydrofuran-2-on zur bekämpfung von psylliden
AR067500A1 (es) Prevencion de la reduccion de enlaces de disulfuro durante la produccion recombinante de polipeptidos
DE602006004186D1 (de) VERFAHREN ZUR HERSTELLUNG EINER NICHTAROMATISCHEN L-AMINOSÄURE UNTER VERWENDUNG EINES BAKTERIUMS DERRESSION DES csrA-GENS
DE602007008731D1 (de) Verfahren zur herstellung einer l-aminosäure unter verwendung eines bakteriums der familie enterobacteriaceae mit abgeschwächter expression des rspab-operons

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application